Another Phase II trial evaluated the oral Mek 1/2 inhibitor selumetinib in 47 patients who were either ≥60 with untreated AML or any age with relapsed/refractory AML [93]. The gene discussed is MAP2K1; the disease is acute myeloid leukemia.